Kornimate/medical-research-clean huggingface dataset:
fluoroscopy activation interval in swl

Conditions: Kidney Calculi

Summary: shock wave lithotripsy (swl) is a noninvasive method widely used as the first step in treating stone disease. this study aimed to reduce radiation exposure to patients and practitioners during swl sessions by extending the intervals of fluoroscopy controls. the main questions it aims to answer are: * will radiation exposure be reduced? * will the stone-free status be affected? the researchers will compare the fluoroscopic control intervals of 250 shocks and 500 shocks. participants will: * take to a maximum of 3 sessions. * check once a week * group 1 was fluoroscopically monitored every 250 shocks, and group 2 was fluoroscopically monitored every 500 shocks

swl works on the principle of focusing on the calculus using ultrasonography or fluoroscopy, transmitting high-energy shock waves from the lithotripter to the calculus and fragmenting it. fluoroscopic focusing is a commonly used imaging technique that raises concerns about ionizing radiation exposure for patients, technologists, and physicians. intermittent fluoroscopic monitoring during swl is widely employed to adjust for patient movement, respiratory movement, and stone displacement within the kidney. however, there is no consensus on the optimal frequency of fluoroscopic monitoring in the literature. this study aims to seek to determine whether increasing the duration between fluoroscopic checks affects the success rate of swl in achieving stone-free status while reducing radiation exposure to patients.

Eligibility criteria:
inclusion criteria: * radiopaque renal pelvic stones smaller than 2 centimeters. exclusion criteria: * anatomical anomalies, coagulation disorders, non-opaque calculi, active urinary infection and distal obstruction

Keywords: kidney stone shock wave lithotripsy radiation
methotrexate for central serous chorioretinopathy treatment trial

Conditions: Central Serous Chorioretinopathy

Summary: central serous chorioretinopathy (csc) is a disease of unknown origin however multiple reports have indicated correlation of appearance of csc with exposure to exogenous or elevated levels of endogenous corticosteroid. since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may be beneficial in reducing this level thus eliminating the stimulus for csc. methotrexate (mtx) is widely used to control different types of inflammation. the investigators are going to try an escalating doses of mtx to treat csc under full medical supervision.

central serous chorioretinopathy (csc) is a disease of unknown origin usually affecting the center of the macula in adults of working age. though previously the condition was considered stress-related, multiple recent reports have indicated correlation of appearance of csc with exposure to exogenous or elevated levels of endogenous corticosteroid. since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may downregulate the endogenous steroids thus eliminating the stimulus for csc. methotrexate (mtx) is widely used to control different types of inflammation. few short retrospective series of beneficial effect of mtx on csc were reported recently. the investigators are going to try an escalating doses of mtx to treat csc under full medical supervision in a prospective manner.

Eligibility criteria:
inclusion criteria: * central serous chorioretinopathy exclusion criteria: * pregnancy * liver disease * kidney disease * steroid use

Keywords: central serous chorioretinopathy methotrexate
phase ii study in patients with operable breast cancer

Conditions: Breast Cancer

Summary: the study will evaluate the safety and efficacy of the combination pld, paclitaxel, and trastuzumab in patients with operable breast cancer. patients will be treated with the combination for 18 weeks, followed by surgery.


Eligibility criteria:
inclusion criteria: * dx of clinical t1c-t3, n0-1, m0 breast cancer * interval between diagnosis and consent of \<- 62 days * life expectancy of 10 years * lvef by muga \>= lower limit of normal for the testing facility * negative serum pregnancy test * adequate bone marrow, renal, liver function * negative bone scan * hrt discontinued before study entry * adequate contraceptive methods exclusion criteria: * male breast cancer * less than 21 years of age * ulceration, infiltration of the skin, complete fixation or severe skin edema * n3 disease in which nodes are matted and fixed * suspicious palpable supraclavicular nodes * ct evidence of malignant internal mammary nodes * pregnancy or breast feeding at time of study entry * prior therapy for breast cancer * prior anthracycline for any malignancy * prior breast malignancy of the contralateral breast * prior non-breast malignancy within 5 years * non-malignant disease that would preclude follow up * mi within 6 months, nyha class ii or greater heart failure * psychiatric disorders or conditions that would preclude provision of informed consent

Keywords: breast cancer over-expressing her2-neu
development and validation of an noninvasive model for predicting high risk esophageal varices in cirrhosis

Conditions: Esophageal and Gastric Varices

Summary: the aim of the study is to develop and validate a new noninvasive method based on routine examination during clinical practice for predicting high risk esophageal varices in cirrhosis.

portal hypertension is the main consequence of cirrhosis. variceal bleeding is the principal and life-threatening complication of portal hypertension. endoscopic screening is the golden standard to detect esophageal varices. however, endoscopy is limited by its invasiveness, cost and the discomfort it imposes on patients. with the goal of circumventing these disadvantages, we intend to develop an noninvasive method for predicting high risk esophageal varices.

Eligibility criteria:
the inclusion criteria: 1. patients who were diagnosed with liver cirrhosis. 2. patients who underwent the abdominal contrast-enhanced ct examination. 3. patients who received endoscopic screening. 4. patients with written informed consent. the exclusion criteria: 1. patients who previously underwent endoscopic therapy, transjugular intrahepatic portosystemic shunt (tips), splenectomy, partial splenic embolization (pse), hepatectomy, balloon-occluded retrograde transvenous obliteration, or liver transplantation. 2. patients with liver cancer. 3. patients with severe ascites or hepatic encephalopathy. 4. lacks abdominal contrast-enhanced ct within 1 month of endoscopy.

Keywords: noninvasive portal hypertension radiomics
the value of second-trimester uterine artery doppler analysis in the prediction of gdm in a low- risk population

Conditions: Gestational Diabetes

Summary: in the current literature, there are not enough studies related to the use of uterine artery doppler indices in the second trimester for the prediction of gdm. considering that it may be useful in the prediction of gdm in low-risk patient groups for gdm, it was found useful to consider uterine artery doppler analysis within the scope of this study.in this study, the investigators aimed to assess the value of second-trimester uterine artery doppler analysis in the prediction of gdm in a low- risk population.

this retrospective research was conducted between june 2020 and december 2021 at the perinatology clinic of haseki training and research hospital. maternal age between 18 and 42 years and gestational age between 18 and 23 weeks were the inclusion criteria.pregnant women's computerized records were used to compare the relevant data of women diagnosed with gestational diabetes and women with normal glucose tolerance . transabdominal ultrasonography was performed for anatomical scanning, and the uterine artery doppler was obtained using ultrasonographic devices with a 2.0-7.0 megahertz convex probe. the uterine artery waveforms were obtained using pulsed-wave doppler with an insonation angle of 30° and a peak systolic velocity greater than 60 cm/s. three identical waveforms were obtained consecutively on each side. in addition to recording the presence or absence of notching, the mean uterine artery pulsatility index (uapi) was also obtained. abnormal uterine artery doppler was defined as a mean uapi greater than the 95th percentile for each gestation.increased uterine artery pulsatility index and/or diastolic notch in the uterine artery between 18-23 weeks of pregnancy can predict the risk of gdm in pregnant women.

Eligibility criteria:
inclusion criteria: • pregnant women with or without gestational diabetes in low- risk population exclusion criteria: * pregestational diabetes * preeclampsia * intrauterine growth restriction * chronic maternal disease
prediction of axillary lymph node metastasis status in breast cancer based on pet/ct radiomics

Conditions: Breast Neoplasms

Summary: patients with suspected breast cancer undergoing pet/ct at our hospital. the pet/ct center's chief physician and senior attending physician reviewed the films together and disagreement, if any, was resolved by consensus. the lesion was visually identified. a 3d region of interest(roi) of the lesion was automatically outlined using the 40% threshold method, and pet metabolic parameters were measured . breast lesions with radionuclide concentrations greater than those in normal breast tissue are considered to be breast cancer lesions, while lymph nodes with radionuclide concentrations greater than those in muscle tissue are considered to be metastatic lymph nodes. image segmentation: image segmentation was performed using itk-snap software (4) (version 3.6.0, http://www.itksnap.org/), brush style: circular, brush size: 10, brush options: 3d. the entire tumor volume was outlined on the pet image as roi for segmentation. an open source python package (pyradiomics version 3.0.1(5)) was used to extract the radiomics features from the roi. univariate and multivariate binary logistic regressions were used to construct model for predicting lymph node metastasis in breast cancer.


Eligibility criteria:
inclusion criteria: * 1) 18f-fdg pet/ct for breast occupancy; 2) adult female patients with pathologically confirmed breast cancer (age ≥18 years); 3) no history of surgery, radiotherapy, or chemotherapy before 18f-fdg pet/ct; and 4) interval between 18f-fdg pet/ct and puncture/surgery ≤2 weeks. exclusion criteria: * 1) multifocal, bilateral, or occult breast cancer; 2) incomplete clinical or pathological data; 3) poor pet/ct image quality, when metabolic tumor volume(mtv) cannot be automatically segmented; and 4) concomitant malignant tumors.
expanding use of cgm in critical care: impact on nurse work patterns and patient outcomes

Conditions: Hyperglycemia

Summary: the primary objective of this implementation study is to assess the feasibility of real time continuous glucose monitoring (cgm) implementation using a cgm plus (+) point-of-care (poc) protocol among patients on iv insulin or those with hyperglycemia (\>250mg/dl) in the critical care hospital environments.

this study analyzes the feasibility of inpatient real time cgm implementation through the use of a cgm + poc protocol as routine care for glycemic monitoring among patients on iv insulin or those with hyperglycemia (\>250mg/dl). the investigators will examine the effects on medical intensive care (micu) patient's (n=100) glycemic control compared to matched historical control patients (n=100) from the micu who received fingerstick poc.

Eligibility criteria:
inclusion criteria: * adults \>18 years old, * admitted to ohio state university wexner medical center micu and * have hyperglycemia (glucose \>250mg/dl) or are currently on iv insulin. exclusion criteria: * current covid-19 infection, * refractory shock (levophed dose \>0.5 mcg/kg/min or equivalent) * actively being treated for diabetic ketoacidosis (dka) * actively being treated for hyperosmolar non-ketoacidosis (honk) * pitting edema, anasarca, blue or purple discoloration to left upper extremity * treated with high dose acetaminophen (\>1 gram q6 hours) * treated with hydroxyurea * are pregnant, patients * using home insulin pump therapy during hospitalization, or * reside in a corrections institution.
optical biometry and spherical aberration in ametropic and emmetropic eyes

Conditions: Refractive Errors; Axial Length, Eye; Corneal Wavefront Aberration

Summary: aberrations play a significant role in the visual process and can be divided in lower-order and higher-order aberrations. the former can be measured using the commercially available iol master (carl zeiss meditec ag, germany) and have profound influence on visual acuity. higher-order aberrations do not significantly influence visual acuity but affect the quality of vision and can cause halos, double vision, and night vision disturbances. background cataract surgery has become a routine procedure in the developed countries. during this surgery, a foldable intraocular lens is usually inserted into the capsular bag. however, these lenses do not account for individual optical biometry data or aberrations. therefore, it is important to provide data for ametropic and emmetropic eyes as this information might improve future intraocular lens design and lead to individually adapted lenses for yielding optimal visual acuity and quality results. the aim of the present study is to clarify the correlation between refractive errors/axial eye length and spherical aberrations of the cornea.


Eligibility criteria:
inclusion criteria: * men and women aged between 40 and 60 years * normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant * normal ophthalmic findings unless the investigator considers an abnormality to be clinically irrelevant exclusion criteria: * presence of any corneal or retinal disease * dry eye syndrome * high astigmatism (\>1 diopter) * history of refractive surgery * abuse of alcoholic beverages * participation in a clinical trial in the 3 weeks preceding the study * symptoms of a clinically relevant illness in the 3 weeks before the study day * pregnancy
rational-emotional behavioral therapy (rebt) in patients with osteoarthritis and concomitant diseases before arthroplasty

Conditions: Depression, Anxiety; Pain

Summary: the objective of this study was evaluation of the effectiveness of rebt on the emotional state of orthopedic patients with comorbidities before and after arthroplasty.

the studies assessed depression or anxiety in orthopedic patients by using spielberger state-trait anxiety inventory (stai) and hospital anxiety and depression scale (hads) before and after athroplasty. the comorbid background studied. the orthopedic patients with comorbidities were divided into several groups: arterial hypertension, chronic pyelonephritis , varicose veins, cardiovascular disease and atherosclerosis, diabetes mellitus, infection diseases, gastrointestinal diseases, obesity, neurological disorder, cerebrovascular accident, iron deficiency anemia, chronic bronchitis, hyperthyroidism, cardiac arrhythmia, other diseases. patients with high levels of anxiety and depression underwent rational emotive behavior therapy before surgery. patients without comorbidities and patients with comorbidities but without exposure considered as a control.

Eligibility criteria:
inclusion criteria: * patients enrolled for the primary knee or hip arthroplasty (m15.0, m16, m17) before operation. exclusion criteria: * other types of psychiatric pathology * reluctance to undergo psychological correction * failure to pass pre-test * ongoing follow-up with a psychologist or psychiatrist

Keywords: depression anxiety rational emotive behavior therapy arthroplasty osteoarthritis comorbidities
risk of hepatitis b reactivation in patients with prior hbv exposure undergoing rituximab-containing chemotherapy: a prospective study

Conditions: Exposure to Hepatitis B Virus

Summary: the purpose of this study is to determine whether preemptive nucleoside analogue therapy or regular virologic monitoring is the preferred method in management patients with prior exposure to hepatitis b vius (hbv) and undergoing rituximab-containing chemotherapy.

occult hepatitis b virus (hbv) reactivation has been documented in patients undergoing rituximab-containing chemotherapy who are hepatitis b surface antigen (hbsag)-negative but with serologic evidence of prior exposure to hbv. however detailed prospective studies documenting the incidence of reactivation and the virologic and serologic kinetics of reactivation are lacking. the investigators prospective study proposes to follow-up 70 such patients with all serologic and virologic parameters monitored every 4 weeks. patients with detectable hbv dna will be started on nucleoside analogue therapy. the optimal method and duration of monitoring will also be determined from our study.

Eligibility criteria:
inclusion criteria: * documented hbsag-negative with or without antibody to hepatitis b surface antigen (anti-hbs) * documented anti-hbc (total)-positive exclusion criteria: * concomitant liver diseases including chronic hepatitis c and d infection, wilson's disease, autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis. * significant alcohol intake (\>30 grams per day)

Keywords: hepatitis b anti-hbc hbsag rituximab occult hbv
a study investigating the efficacy and safety of ociperlimab and tislelizumab and bat1706 combinations in patients with advanced hcc

Conditions: Advanced Hepatocellular Carcinoma

Summary: this was a phase 2, randomized, multicenter, open-label, 2-arm study to investigate the efficacy and safety of ociperlimab in combination with tislelizumab plus bat1706, and tislelizumab plus bat1706, as first-line treatment in participants with advanced hepatocellular carcinoma (hcc).


Eligibility criteria:
criteria: inclusion criteria: 1. histologically confirmed hcc 2. barcelona clinic liver cancer (bclc) stage c disease, or bclc stage b disease that was not amenable to or had progressed after loco-regional therapy, and was not amenable to a curative treatment approach 3. tumor tissue required for an evaluable programmed cell death protein-ligand 1 (pd-l1) expression result 4. no prior systemic therapy for hcc 5. at least 1 measurable lesion as defined per recist v1.1 6. adequate organ function during screening and before randomization exclusion criteria: 1. known fibrolamellar hcc, sarcomatoid hcc, or mixed cholangiocarcinoma and hcc histology 2. prior therapy with antibody or drug specifically targeting t-cell costimulation or checkpoint pathway; prior treatment with bevacizumab or its biosimilars 3. prior history of \>= grade 2 hepatic encephalopathy 4. leptomeningeal disease or uncontrolled, untreated brain metastasis 5. active autoimmune diseases or history of autoimmune diseases that may relapse 6. history of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases 7. infection (including tuberculosis) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days of randomization 8. prior allogeneic stem cell transplantation or organ transplantation 9. significant cardiovascular risk factors 10. untreated or incompletely treated esophageal or gastric varices with bleeding or high risk of bleeding 11. history of severe hypersensitivity reactions to other monoclonal antibodies 12. administered a live vaccine \<=28 days before randomization note: other protocol inclusion/exclusion criteria may apply
lanreotide as treatment of polycystic livers

Conditions: Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney, Autosomal Dominant

Summary: to assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed. a minimum of 38 patients will be recruited and randomized (1:1) to receive either verum or placebo. lanreotide is already used in other disease states and found to be safe and non-toxic.


Eligibility criteria:
inclusion criteria: * 18 yrs-of age * multiple cysts \> 20 * cooperating patient * is willing and able to comply with the study drug regimen and all other study requirements * willingness to give written informed consent exclusion criteria: * use of oral anticonceptives or estrogen suppletion * females who are pregnant or breast-feeding * history or other evidence of chronic pulmonary disease associated with functional limitation * history of severe cardiac disease * history or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study * symptomatic gallstones * renal failure requiring hemodialysis

Keywords: polycystic liver disease autosomal dominant polycystic kidney disease liver cyst lanreotide
functional dyspepsia treatment using virtual reality

Conditions: Functional Dyspepsia

Summary: the purpose of this study is to evaluate the effectiveness of using virtual reality to treat gastrointestinal symptoms related to functional dyspepsia.


Eligibility criteria:
inclusion criteria: * symptoms of dyspepsia thought to represent functional dyspepsia, meeting rome iv criteria * had an upper endoscopy and assessment for helicobacter pylori; if a patient is found to have h. pylori, treatment with confirmed eradication (by stool antigen test or urea breath test) will be required before the patient is eligible for study inclusion. * patients will be considered for the study if they have undergone a complete history and physical examination during a previously scheduled consultation/evaluation visit with a gastroenterologist in the mayo clinic florida general gi or motility clinic. exclusion criteria: * symptoms are thought to represent an organic disorder (e.g., peptic ulcer disease, hepatitis, pancreatitis, inflammatory bowel disease, type i diabetes, a known malignancy, radiation-induced injury, an active infection, vasculitis, celiac disease), or patients have known uncontrolled gerd, esophagitis, eosinophilic esophagitis, or untreated h. pylori. * patients with gastroparesis or cyclic vomiting syndrome. * patients with prior surgery to the esophagus, stomach or duodenum. * patients taking opioids. * patients with motion sickness, vertigo, or a seizure disorder * ibs symptoms are not predominant.